Unauthorized Use of Content on this Site: The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB)—including, but not limited to, those available through the PAAB Forum, the PAAB website, and any PAAB correspondence—are specifically intended to assist individuals navigating the PAAB preclearance system. Repurposing or reproducing this content, or using it for model training or any related purposes, is strictly prohibited without the express prior written consent of PAAB. This includes, but is not limited to, the use of such materials in automated systems, machine learning models, or artificial intelligence applications.
Third-Party Unbranded Patient App - Communications
-
Would a leaflet that explains the benefits of a third party developed patient app being disseminated to patients via a branded PSP require PAAB review? The leaflet would not mention the specific PSP or brand. It would only discuss the app. The app itself was reviewed as part of a branded patient brochure under 'addition lifestyle resources' and was deemed acceptable by PAAB.
-
Hey @danielle
If the leaflet was produced by the third party developed patient app, and there were no implications for outcomes which could be associated to the brand, it would likely not require PAAB review. As an example, an independent third-party medication reminder and adherence tracker's promotional leaflet which spoke to the features of the app would likely be exempt. If that leaflet contained outcomes that could be expected, improved etc. as a result of proper adherence, this would likely not be exempt. PAAB can provide an opinion through the opinion service if you’re not sure if the leaflet would fall into this category.
